Table 5.

Temodar use by various characteristics and by histologic type (excluding those with unknown temodar use) N=479, San Francisco Bay Area Adult Glioma Study (2001–2005)

	GBM				Non-GBM
	Used Temodar		No Temodar		Used Temodar		No Temodar
	n	row %	n	row %	n	row %	n	row %
Ethnicity
Non-White	41	63	24	37	21	41	30	59
White	145	62	88	38	53	41	77	59
Age
<50	52	76	16	24	48	41	70	59
50–59	46	68	22	32	14	47	16	53
60–69	58	69	26	31	9	47	10	53
70+	30	38	48	62	3	21	11	79
Gender
Female	71	55	58	45	28	35	53	65
Male	115	68	54	32	46	46	54	54
Proxy Status
Self report	154	76	48	24	71	43	95	57
Proxy report	32	33	64	67	3	20	12	80
Blood collection status
No blood collected	27	29	65	71	7	26	20	74
Blood collected	159	77	47	23	67	44	87	56
Total IgE
IgE missing	29	31	65	69	7	26	20	74
Normal IgE	88	81	21	19	33	45	41	55
Borderline IgE	35	71	14	29	25	49	26	51
Elevated IgE	34	74	12	26	9	31	20	69
Diagnosis Year
Dx Year 2001	2	14	12	86	2	29	5	71
Dx Year 2002	49	60	32	40	22	31	49	69
Dx Year 2003	67	59	46	41	32	48	35	52
Dx Year 2004	68	76	22	24	18	50	18	50
Allergy History
No Reported Allergy History	48	59	33	41	11	42	15	58
Reported Allergy History	138	64	79	36	63	41	92	59
Education
Not a College Graduate	89	57	67	43	33	40	50	60
College Graduate	97	68	45	32	41	42	57	58

bold percentages indicate that the chi-square p-value is less than 0.05.